非类固醇抗炎药物和实验性查加斯病:一个未解决的问题
Scheila Thaís Nicolau1, Daniela Patrícia Tres1, Thaís Soprani Ayala1
1Laboratory of Applied Immunology, Center of Medical and Pharmaceutical Sciences, Western Parana State University, Cascavel, Brazil.
Parasite immunology
|July 15, 2024
概括
非类固醇抗炎药物 (NSAIDs) 通过改变脂质介质通路,在实验模型中影响查加斯病的进展. 了解这些影响对于理解Trypanosoma cruzi感染病原体至关重要.
科学领域:
- 寄生虫学的寄生虫学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 查加斯病是由Trypanosoma cruzi引起的,呈现急性和慢性阶段,潜在的心脏和胃肠道问题.
- 小鼠是常见的实验模型,但它们的感染动态因宿主,寄生虫菌株,剂量和施用途径而异.
- 像前列腺素和血栓这样的脂质介质是T. cruzi感染病原体的关键,有助于急性阶段的免疫抑制.
研究的目的:
- 研究非类固醇抗炎药物 (NSAIDs) 在调节实验性查加斯病中的作用.
- 阐明NSAID诱导的eicosanoid抑制如何影响T. cruzi感染动态在体外和体内.
- 通过实验模型和NSAID干预的透视来增强对查加斯病的发病机制的理解.
主要方法:
- 使用查加斯病的实验模型 (体外和体内).
- 使用非类固醇抗炎药物 (NSAIDs) 调节eicosanoid通路.
- 分析NSAIDs对T. cruzi感染和疾病进展的动态的影响.
主要成果:
- 非类固醇抗炎药物 (NSAIDs) 显著改变了实验性查加斯病的过程.
- 通过NSAIDs抑制eicosanoid会影响Trypanosoma cruzi感染的发生.
- 由于不同的阻塞机制,各种NSAIDs表现出不同的效果.
结论:
- 无抗炎药在调节实验性查加斯病方面发挥着重要作用,为病变发生提供了洞察力.
- 了解NSAIDs,脂质调解剂和T. cruzi之间的相互作用对于推进查加斯病研究至关重要.
- 对NSAID作用的进一步调查可以提高对这种复杂的寄生虫感染的理解.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
156
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
156
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
128
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
128
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
486
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
486